迪哲医药两款全球首创新药高瑞哲、DZD8586亮相血液瘤顶会

Core Viewpoint - DIZHE Pharmaceutical is set to present significant research advancements for its innovative drugs, Golixty and DZD8586, at the upcoming 2025 European Hematology Association (EHA) annual meeting and the 18th International Conference on Malignant Lymphoma (ICML) [2] Group 1: Golixty for PTCL - Golixty offers new hope for patients with Peripheral T-cell Lymphoma (PTCL) who experience relapse after first-line treatment, with approximately 40% of patients achieving complete remission (CR) and 80% achieving partial remission (PR) relapsing within two years [3] - A Phase II prospective multicenter clinical study shows that Golixty maintenance therapy after first-line systemic treatment results in a 24-month disease-free survival rate of 74.2% for CR1 patients, and a 50.0% complete remission rate with a median duration of response of 23.9 months for PR patients [3] - Golixty is a new generation, oral, highly selective JAK1 inhibitor that may address the lack of effective maintenance treatment options for PTCL, demonstrating significant anti-tumor activity and safety [4] Group 2: DZD8586 for B-NHL - DZD8586 shows promise as a new treatment strategy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), with an objective response rate of 84.2% in patients previously treated with various therapies [5] - The drug exhibits significant anti-tumor efficacy and good safety profile, with no observed drug-related bleeding, atrial fibrillation, or major cardiac risks [6] - DZD8586's potential to overcome limitations of traditional small molecule drugs in treating Diffuse Large B-cell Lymphoma (DLBCL) is highlighted, as it blocks BTK and LYN signaling pathways, improving clinical outcomes [6] Group 3: Company Commitment - DIZHE Pharmaceutical's founder and CEO expresses excitement over the clinical potential of Golixty and DZD8586 in addressing significant unmet needs in PTCL and B-NHL, emphasizing the recognition of their innovative capabilities [6]